OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
Company Appoints Nationally Renowned Expert in Targeted Therapies for Melanoma to Clinical Leadership Role
SAN DIEGO-- OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Adil Daud, M.D. as Chief Clinical Strategist.
Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory Board and serves as Principal Investigator for OncoSec’s Phase 2 melanoma study. He is a clinical professor of hematology/oncology at University of California, San Francisco (UCSF), and Director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Daud is a nationally recognized expert in early-phase drug development in skin cancer and solid tumors, and has co-authored more than 60 scientific publications. Prior to joining UCSF in 2008, Dr. Daud served at Memorial Sloan-Kettering Cancer Center in New York and H. Lee Moffitt Cancer Center in Florida. He has been the recipient of numerous awards, including the American Society for Clinical Oncology’s Young Investigator award and Castle Connolly’s Best Doctors in America award.
Dr. Daud said, “I am both honored and excited to take on this expanded role as Chief Clinical Strategist for OncoSec Medical. I believe this is a watershed moment in oncology, and that intralesional therapies like those being advanced by the OncoSec team have the potential to provide serious benefit to many patients around the globe.”
“Dr. Daud is a pioneer in the field of gene-electro therapy,” said Punit Dhillon, President and CEO. “His Phase I study investigating the use of in-vivo electroporation to deliver plasmid DNA laid the groundwork for OncoSec’s formation, and his efforts have proved integral to the company’s development. Adil’s work continues to support his status as a key opinion leader in intralesional immunotherapies.”
As Chief Clinical Strategist, Dr. Daud will take on an expanded clinical leadership role. Among his central duties will be to advise on protocol and development, liaise with key stakeholders and represent the company at conferences and other important events.
Said Robert Pierce, M.D., Chief Medical Officer, “Working with Adil has been a pleasure. Together, our team looks forward to driving the clinical development of our pIL-12-based ImmunoPulse in melanoma and other solid tumor indications, as well as delivering new drug candidate INDs.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination therapeutic approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
OncoSec Medical Inc.
Veronica Vallejo, CFO
Source: OncoSec Medical Inc.